160 related articles for article (PubMed ID: 26510968)
1. Artificial signal transduction therapy: a futuristic approach to disease treatment.
Peri-Naor R; Motiei L; Margulies D
Future Med Chem; 2015; 7(16):2091-3. PubMed ID: 26510968
[No Abstract] [Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.
Chen MH; Kerkelä R; Force T
Circulation; 2008 Jul; 118(1):84-95. PubMed ID: 18591451
[No Abstract] [Full Text] [Related]
5. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase inhibitors.
Crescenzo R; Inghirami G
Curr Opin Pharmacol; 2015 Aug; 23():39-44. PubMed ID: 26051994
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor WR; Salas AROSE; Melo FHM
Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Di Lorenzo L
J Clin Oncol; 2007 Jul; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
[No Abstract] [Full Text] [Related]
11. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
[No Abstract] [Full Text] [Related]
12. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
13. Exploiting receptor tyrosine kinase co-activation for cancer therapy.
Tan AC; Vyse S; Huang PH
Drug Discov Today; 2017 Jan; 22(1):72-84. PubMed ID: 27452454
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE; Karamanos NK
In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
[TBL] [Abstract][Full Text] [Related]
15. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of targeted interference with Src-mediated signal transduction events.
Ly QP; Yeatman TJ
Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
[No Abstract] [Full Text] [Related]
17. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
18. [Signal transduction by protein tyrosine kinases and antitumor agents].
Mao YJ; Li HH; Li JF; Shen JS
Yao Xue Xue Bao; 2008 Apr; 43(4):323-34. PubMed ID: 18664191
[TBL] [Abstract][Full Text] [Related]
19. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for solid tumors: current status.
Zureikat AH; McKee MD
Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
